<DOC>
	<DOC>NCT00600964</DOC>
	<brief_summary>This protocol is being run to determine the best phase II dose and schedule of obatoclax in patients with previously untreated CLL.</brief_summary>
	<brief_title>A Phase I/II Study of GX15-070MS in Untreated CLL</brief_title>
	<detailed_description>Both 1 hour and 3 hour infusions of obatoclax every 3 weeks will be evaluated in ascending doses.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<criteria>Histologically or cytologically confirmed BCLL Previous standard systemic chemotherapy, including fludarabine. There are no limitations on additional, allowable type and amount of prior therapy. Acute toxicities from prior therapy must have resolved to ≤Grade 1 Age ≥18 years ECOG Performance Status ≤1 Life expectancy of &gt;8 weeks Patients receiving any other investigational agents (e.g., under another IND) or commercial agents or therapies administered with the intent to treat their malignancy Patients with history of seizure disorders Pregnant women and women who are breast feeding HIVpositive patients receiving combination antiretroviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>CLL</keyword>
	<keyword>obatoclax</keyword>
</DOC>